FIRE1 Norm System Congestion Score Highlighted as Late-Breaking Science at HFSA 2025
FIRE1’s Norm System and Congestion Score Highlighted as Late-Breaking Science at HFSA 2025 FIRE1, a pioneering company in connected medical device solutions, has announced that its innovative heart failure management…
WINREVAIR™ Cuts PAH Clinical Worsening Risk by 76%
Merck Reports Clinical Positive Phase 3 HYPERION Trial Results for WINREVAIR™ (sotatercept-csrk) in Newly Diagnosed Pulmonary Arterial Hypertension Patients Merck known as MSD outside the United States and Canada, today…
Endeavor BioMedicines Shares Positive Phase 2a Taladegib Data
Endeavor BioMedicines Reports Positive Phase 2a Results for Taladegib in Idiopathic Pulmonary Fibrosis, Published in The Lancet Respiratory Medicine Endeavor BioMedicines (“Endeavor”), a clinical-stage biotechnology company focused on developing transformative…
HELIOS-B Phase 3: Vutrisiran Shows Fewer GI Events in ATTR-CM Patients
Alnylam Pharmaceuticals Reports HELIOS-B Phase 3 Findings: Vutrisiran Reduces Gastrointestinal Events in ATTR-CM Patients Alnylam Pharmaceuticals, Inc. , a global leader in RNA interference (RNAi) therapeutics, today unveiled new analyses…
Balchem Showcases Vitamin K2 at FC Bayern Women’s Season Opener
Balchem Kicks Off New Era of Consumer Engagement: Showcasing the Power of Vitamin K2 at FC Bayern Women’s Season Opener When tens of thousands of fans poured into Munich’s Allianz…
International Day of Older Persons: AOP Health Raises Awareness of the Hidden Burden of Venous Leg Ulcers
International Day of Older Persons: AOP Health Brings Urgent Attention to the Silent Burden of Venous Leg Ulcers Every year on October 1, the world observes the United Nations’ International…
ENHERTU Shows Superior Results Over T-DM1 in DESTINY-Breast05 Trial
ENHERTU® Demonstrates Significant Superiority Over T-DM1 in DESTINY-Breast05 Phase 3 Trial for High-Risk HER2 Positive Early Breast Cancer Patients Positive topline results from the planned interim analysis of the DESTINY-Breast05…
Savara Shares Phase 3 IMPALA-2 Trial Results of Molgramostim in aPAP at ERS 2025
Savara Presents New Phase 3 IMPALA-2 Data on Molgramostim for Autoimmune Pulmonary Alveolar Proteinosis at ERS Congress 2025 Savara Inc. (Nasdaq: SVRA), a clinical-stage biopharmaceutical company dedicated to developing therapies…
Quince Therapeutics Publishes eDSP PopPK Modeling Study in CPT: PSP
Quince Therapeutics Publishes Advanced Population PK Modeling Study of eDSP in Pediatric Ataxia-Telangiectasia Patients in CPT: Pharmacometrics & Systems Pharmacology Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company pioneering…
Lundbeck Partners with Migraine Community to Elevate Standards of Migraine Care
Lundbeck Partners with Migraine Community to Transform Care and Improve Lives Despite being recognized as one of the leading causes of disability worldwide, migraine remains widely misunderstood, and the profound…
Bayer Canada Forms Distribution Partnership for ADALAT® XL 30 mg Tablets
Bayer Canada Partners with Mint Pharmaceuticals to Enhance Access to ADALAT® XL 30 mg Tablets Across the Country Bayer Canada has announced a significant new partnership with Mint Pharmaceuticals Inc.…
TAE Life Sciences, UW-Madison Introduce BNCT Cancer Therapy in U.S.
TAE Life Sciences and University of Wisconsin–Madison Collaborate to Bring Revolutionary Accelerator-Based BNCT Cancer Therapy to the U.S. TAE Life Sciences (TLS), a global innovator in the field of advanced…